359	O
Delayed	O
Treatment	O
of	O
Ruptured	B:C3203359
Arteriovenous	B:C0334533
Malformations	I:C0334533
:	O
Is	O
It	O
Ok	O
to	O
Wait	O
?.	O

Emergent	O
surgery	B:C0543467
on	O
a	O
ruptured	B:C3203359
brain	B:C0006104
arteriovenous	B:C0334533
malformation	I:C0334533
(	O
arteriovenous	B:C0334533
malformation	I:C0334533
)	O
is	O
indicated	O
for	O
a	O
large	O
hematoma	B:C0018944
in	O
an	O
acutely	O
deteriorating	B:C1457868
patient	O
.	O

The	O
majority	O
of	O
ruptured	B:C3203359
AVMs	B:C0334533
,	O
however	O
,	O
present	O
in	O
clinically	O
stable	O
patients	O
with	O
neurological	B:C0521654
deficits	I:C0521654
.	O

Controversy	O
exists	O
with	O
respect	O
to	O
the	O
timing	O
of	O
treatment	O
for	O
ruptured	B:C3203359
AVMs	B:C0334533
in	O
these	O
stable	O
patients	O
.	O

This	O
study	B:C2603343
aims	O
to	O
determine	O
the	O
safety	O
of	O
delaying	O
arteriovenous	B:C0334533
malformation	I:C0334533
treatment	O
in	O
clinically	O
stable	O
patients	O
by	O
investigating	O
the	O
rate	O
of	O
rehemorrhage	B:C0019080
in	O
a	O
cohort	B:C0599755
of	O
patients	O
with	O
ruptured	B:C3203359
brain	B:C0006104
AVMs	B:C0334533
.	O

Patients	O
presenting	O
to	O
our	O
institution	B:C2607850
from	O
January	O
2000	O
to	O
December	O
2015	O
with	O
ruptured	B:C3203359
brain	B:C0006104
AVMs	B:C0334533
treated	O
at	O
least	O
4	O
weeks	O
posthemorrhage	B:C0919874
were	O
included	O
in	O
the	O
analysis	B:C0936012
.	O

Exclusion	O
criteria	O
were	O
ruptured	B:C3203359
AVMs	B:C0334533
that	O
required	O
emergent	O
surgery	B:C0543467
involving	O
arteriovenous	B:C0334533
malformation	I:C0334533
resection	B:C0015252
,	O
previous	O
treatment	O
at	O
another	O
institution	B:C2607850
,	O
or	O
subacute	O
arteriovenous	B:C0334533
malformation	I:C0334533
treatment	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
time	O
from	O
initial	O
hemorrhage	B:C0019080
to	O
rehemorrhage	B:C0019080
.	O

Patient	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
data	O
were	O
included	O
up	O
until	O
the	O
point	O
of	O
arteriovenous	B:C0334533
malformation	I:C0334533
treatment	O
.	O

Of	O
the	O
103	O
ruptured	B:C3203359
AVMs	B:C0334533
(	O
49	O
M:54	O
F	O
)	O
meeting	O
inclusion	O
criteria	O
,	O
the	O
median	O
time	O
from	O
rupture	B:C3203359
to	O
treatment	O
or	O
rehemorrhage	B:C0019080
was	O
112	O
days	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
:	O
110	O
)	O
.	O

Six	O
(	O
5.8	O
%	O
)	O
patients	O
rehemorrhaged	B:C0019080
in	O
a	O
median	O
of	O
248	O
days	O
(	O
IQR	O
:	O
1331	O
)	O
.	O

Two	O
of	O
these	O
patients	O
rehemorrhaged	B:C0019080
on	O
the	O
same	O
day	O
of	O
their	O
index	O
hemorrhage	B:C0019080
.	O

The	O
total	O
at	O
-	O
risk	O
period	O
was	O
19	O
445	O
patient	O
-	O
days	O
,	O
yielding	O
a	O
rehemorrhage	B:C0019080
risk	O
of	O
11.3	O
%	O
per	O
patient	O
-	O
year	O
,	O
or	O
0.93	O
%	O
per	O
patient	O
-	O
month	O
.	O

Our	O
data	O
support	O
stabilizing	O
a	O
patient	O
after	O
the	O
initial	O
arteriovenous	B:C0334533
malformation	I:C0334533
rupture	B:C3203359
.	O

Delaying	O
intervention	O
for	O
4	O
weeks	O
after	O
initial	O
hemorrhage	B:C0019080
subjects	O
the	O
patient	O
to	O
a	O
low	O
(	O
<	O
1	O
%	O
)	O
risk	O
of	O
rehemorrhage	B:C0019080
.	O

